BeOne Medicines Ltd. (NASDAQ:ONC) is one of the top high growth international stocks to buy right now. On September 9, Citizens JMP analyst Reni Benjamin reiterated a Buy rating on BeOne Medicines Ltd. (NASDAQ:ONC) and set a price target of $348.00.
On August 29, BeOne Medicines Ltd. (NASDAQ:ONC) announced positive topline results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL), stating that the study met its primary endpoint of overall response rate (ORR) and exhibited clinically meaningful responses in rare B-cell lymphoma with considerable unmet need.
Management added that BeOne Medicines Ltd. (NASDAQ:ONC) would submit the data to global regulatory authorities for their review and potential approval.
Domiciled in Switzerland, BeOne Medicines Ltd. (NASDAQ:ONC) is a global oncology company that discovers and develops affordable, accessible, and innovative treatments for cancer patients.
While we acknowledge the potential of ONC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article is originally published at Insider Monkey.
-1024x683.jpg "Congress Is Back – And ‘Busy’ Ahead of Midterms")
